Goiter
	Kopp et al., Chicago, IL, tested the presence of mutations in the TSH receptor or in the Gsa unit in 33 thyroid nodules from 6 hyperthyroid and 3 euthyroid patients with multinodular goiter. These studies were performed as such mutations have been found to cause toxic adenoma. No mutations were found that could increase cyclic AMP synthesis (as is the case in toxic adenoma) and it is concluded that this type of mutation does not play an important role in the genesis of multinodular goiter. Duntas et al., Athens and Thessaloniki, Greece, treated 10 women with hypothyroid goiter with a slow-release T4 tablet once a week, containing 1 mg L-T4, and compared the results in 10 other similar women, who were treated with 1 tablet daily, containing 100 µg L-T4. Baseline serum thyroid hormone parameters were similar and increased to similar mean levels during the treatment period. Goiter reduction was also similar after 12 weeks treatment (32% and 28% respectively). The only advantage was the fact that the women expressed a preference for the slow-release form as it would improve compliance. (Comment: The statement, that compliance was better in the depot preparation, is not underlined by the facts as the effects on serum thyroid hormone parameters and thyroid reduction were quite similar in both groups.)